On the less encouraging side of things, the authors also identified an increase in heart failure incidence among acute myocardial infarction (MI) patients and patients with atrial fibrillation (AFib).
This finding, the team noted, shows areas where there is still a critical need for better heart failure prevention strategies.
“Management of patients with coronary artery disease and other risk factors, such as diabetes, with novel therapies like sodium-glucose cotransporter 2 inhibitors may reduce the downstream risk of heart failure,” wrote lead author Rohan Khera, MD, MS, department of internal medicine at Yale School of Medicine in New Haven, Connecticut, and colleagues. “In addition, more effective and evidence-based management of AFib with rhythm control strategies, such as catheter ablation, may also contribute to lower heart failure risk. Future studies are needed to assess whether greater uptake of these therapeutic strategies over time may alter the trajectory of heart failure incidence among these patient populations.”
The full JAMA Network Open study can be read here.